Table 2.

Outcomes at end of study (median time of 134 weeks)

Data	Immediate n = 24	Defer n = 19	P
HIV-related illness
No. patient (%)	4 (16.7)	-	0.118
Adverse events
No. patient (%)	22 (91.7)	19 (100)	0.495
No. event (% per month)	100 (13.3)	97 (17.0)	0.081
ARV-related adverse events
No. patient (%)	7 (29.2)	4 (21.1)	0.728
No. event (% per month)	10 (1.3)	5 (0.7)	0.467
Median weight for age Z-scores (IQR)	-1.1 (-1.5 to -0.8)	-1.0 (-1.7 to 0.2)	0.525
Median height for age Z-scores (IQR)	-1.4 (-2.0 to -0.8)	-0.8 (-1.3 to -0.4)	0.171
Median CD4% (IQR)	31 (24 – 39)	23 (17 – 31)	0.032
Median CD4% change (IQR)	13.5 (4 – 18)	3 (-2 to 13)	0.012
Median viral load*, log (IQR)	1.7 (1.7 – 2.5)	3.1 (1.7 – 4.5)	0.039
Median change viral load, log (IQR)	-2.8 (-3.4 to -1.9)	-1.8 (-3.2 to -0.3)	0.079
Median Hemoglobin, g/dL (IQR)	11.7 (10.9 – 12.5)	11.7 (10.9 – 12.5)	0.961
Median alanine transferase, unit/mL (IQR)	15 (12.3 – 21.8)	18 (14 – 23)	0.418
Median triglyceride, mg/dL (IQR)	72 (46 – 109)	98 (61 – 156)	0.106
Median cholesterol, mg/dL (IQR)	158 (152 – 202)	160 (143 – 180)	0.197
Median glucose, mg/dL (IQR)	77 (67 – 87)	76.5 (72.3 – 90.5)	0.833

*Median viral load in the 10 deferred arm children who started ART was 1.7 log (IQR 1.7–1.7) which was similar to that in the immediate arm children (p = 0.58)